📣 Join the MICROB-PREDICT Consensus Conference in Barcelona (for #EASLCongress attendees only)
📅 27 May 2026
⏰ 15:30 – 18:30 h
Experts will discuss #microbiome mechanisms and biomarkers to improve patient stratification and therapeutic response in #cirrhosis and #ACLF.
@easlnews.bsky.social
A big step towards precision medicine!
🎥 youtu.be/pgrQVn8mPbk
Researchers at OUH are validating #biomarkers to predict which #cirrhosis patients may benefit from #albumin therapy - helping deliver the right treatment to the right patient
💡 Double-blind clinical ABL-Trial ongoing
#LiverDisease #ACLF
Alexandra Phillips (UCL) on pre-clinical research in animal models of #LiverFailure and #ACLF, showing how #albumin infusions reduce endotoxin sensitivity by modulating TLR4-driven #inflammation to protect against multi-organ injury.
🎥: youtu.be/SIi906R9DZI
@ucl.ac.uk
@rajivjalan.bsky.social
📣 New publication introducing the A-TANGO Organ Failure (OF) score for improved detection of acute-on-chronic liver failure #ACLF in patients with acute #decompensation of #cirrhosis
👍3,896 patients
👍validated in India & China
👍improves diagnostic accuracy
www.sciencedirect.com/science/arti...
🥳 Congratulations, David Tornai et al. from Maria Papp's team at the University of Debrecen! The paper has been viewed more than 625 times since its publication in Dec 2025 & is currently amongst the top-downloaded articles!
#SerumVillin #GutBarrier #ACLF
📰 onlinelibrary.wiley.com/doi/10.1111/...
🚀 Motivation boost to kick off the new year 🙂: The European Commission agreed to provide a 6-month-long extension to A-TANGO! Let's use this momentum and move forward swiftly now, so that A-TANGO can bring the much-needed G-TAK therapy for severe #AlcoholicHepatitis #cirrhosis #ACLF to the market.
🥂 We have good news for the holidays: The technical hold-up in the EU portal has finally been resolved & we submitted the 3rd #PeriodicReport ☺️
Wishing everyone relaxing holidays❄️
Together, we are moving from bench to bedside to bring innovative therapies to #ACLF patients
@rajivjalan.bsky.social
👏 New study from Dávid Tornai and colleagues 🎉: Serum #Villin1 is a promising non-invasive marker of #GutBarrier damage in #cirrhosis and #ACLF.
It rises with severity, predicts 90-day mortality, links to #inflammation, and has been validated in an independent cohort!
📜 doi.org/10.1111/apt....
📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
New DECISION study in @jhepatology.bsky.social: maladaptive emergency granulopoiesis predicts poor outcomes in acutely #decompensatedcirrhosis.
This could guide early identification and novel therapies.
www.sciencedirect.com/science/arti...
#ACLF #LiverSky #Hepatology @easlnews.bsky.social
🎉 Our new #mirobiome paper in #JHEP is out! We found distinct gut #virome shifts in #ACLF - from virulent to temperate #phages - with Lactococcus A + Enterococcus B phages linked to infections & higher 90-day mortality
👉 Read more: www.sciencedirect.com/science/arti...
📽️Video: youtu.be/0YF6qToBQUM
👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
The latest DECISION Masterclass is live!
💡 Clinical Bioinformatics – It’s More Than Pressing a Button with Núria Planell, Cristina Sanchez & David Gomez-Cabrero.
Watch here: https://youtu.be/UBm1_JGhw6M
#Bioinformatics #ClinicalResearch #ACLF
🚨 New #LiverFailure insights 🚨
In patients with #cirrhosis + acute #decompensation, secretory #IgA strongly correlates with #gut-barrier failure and is a powerful predictor of 90-day mortality in acute-on-chronic #LiverFailure #ACLF
👉 Watch on YouTube: youtu.be/KapUqG7AFFk
#Biomarkers #GutBarrier
For #WorldHepatitisDay we stand together 🩺
At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️
Every person deserves timely, effective, and #stigma‑free support 💪
@europeliver.bsky.social
@who.int
🎥 New keynote online!
Prof. Richard Moreau, Director of #EFCLIF, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency.
Watch now 👉 https://youtu.be/KWoUbTsNjQM
#LiverSky #Hepatology
What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
It's finally here! Consensus #ACLF & #cirrhosis organ failure definitions. ⤵️
pubmed.ncbi.nlm.nih.gov/40499736/
Why? We need to speak the same language re #ACLF
How? Multi-country consensus panels
Result? Harmonized definitions & research agenda @aasldnews.bsky.social @easlnews.bsky.social
📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
#LiverResearch team #HEPEX-Lab @meduniwien.ac.at is affiliated w Center for Molecular Medicine @cemm.oeaw.ac.at
@KatjaSommer #Gut-Liver-Axis
@VladTaru #LiverFailure #ACLF
@BenHofer #Cirrhosis #Recompensation
@KathiBonitz restaurative #Macrophages
@ThomasSorz #AI Patho Spatial Transcritomics
Using this for the final #ConsensusConference of A-TANGO - to evaluate #GTAK trial outcomes & agree on the best treatment for #LiverPatients with #ACLF.
👉 The name comes from the ancient Greek „Oracle of Delphi“ 🔮🇬🇷
👉 The Delphi Method evolved during the Cold War for strategic military decisions 🕊️☮️
Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk.
@rwth.bsky.social
@brunslab.bsky.social
@easlnews.bsky.social
#Cirrhosis #ACLF #EASL2025"
Great talk by Frederike Krus on the hepatic Leptin clearance in #ACLF at the poster tour. #EASLCongress #EASL2025
👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
🥳 SATURDAY 🥳
If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité
#AlcoholicHepatitis #cirrhosis #ACLF #inflammation
@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social
Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
👏 What an accomplishment 🥳
Frederike Krus selected for this afternoon's #PosterTour at #EASLCongress
👉 POSTER ID FRI-175
Loss of hepatic #leptin clearance is associated with the development of #ACLF, acute-on-chronic #LiverFailure
📍 #Cirrhosis & Complications
📅 Fri, 9 May
@medblab.bsky.social
🌟 Rising star - first big conference for him, so give him an applause 👏!
Hendrik Rogge presents a great #poster today at #EASLCongress about the 📊 prediction of circulatory failure in intensive-care #patients with liver #cirrhosis & #ACLF.
👉 #POSTER FRI-182, up until 17h
@medblab.bsky.social
Hendrik Rogge presents his poster on circulatory failure prediction in #ACLF patients. #EASLCongress #EASL2025
Is Leptin involved in progression of #ChronicLiverDisease to #ACLF? Find it out at poster FRI-175 from Frederike Krus. #EASLCongress #EASL2025
